News

Concert Pharmaceuticals Says Potential CF Drug Shows Good Safety Profile in Phase 1 Study

Concert Pharmaceuticals, Inc., which is developing new small molecule drugs through its DCE (deuterated chemical entity) Platform, recently announced positive results from a Phase 1 clinical trial of its cystic fibrosis (CF) treatment, CTP-656 (deuterium-modified ivacaftor). The data, which included a positive safety and tolerability profile, support the continuing development of CTP-656 as…

Lung Exacerbations in Young CF Patients Linked to Poorer Quality of Life

Pulmonary exacerbations have a negative impact on the general health-related quality of life in people with cystic fibrosis (CF), a study reported, stressing the importance of preventing such flares in this group. Assessing general, as opposed to disease-specific, health-related quality of life measures are needed when comparing different disease conditions and determining the usefulness of…

Pilot Program to Help CF Families Navigate Care Systems Reports Initial Success

ACT.md recently reported positive preliminary results from a multiyear project — in partnership with Boston Medical Center and Baystate Health — using the company’s “Collaborative Consultative Care Coordination Program” (4C) to measure improvements in quality of life, family engagement, and healthcare costs for children affected by medically complex conditions like cystic fibrosis. First results…

European Medicines Panel Favors ‘Orphan Product’ Designation for Drug to Treat CF Lung Infections

The European Medicines Authority’s Committee for Orphan Medicinal Products (COMP) has issued a positive opinion recommending the designation of orphan medicinal product to Arch Biopartners Inc.‘s AB569 as a potential treatment of infections in cystic fibrosis (CF) patients. AB569 was invented at the University of Cincinnati (UC) in the laboratory…

Natural Treatments of Little Benefit on Their Own to CF Patients, But Potential Seen for Drug Development

A Chicago Medical School review explored the scientific evidence behind three natural compounds — genistein, curcumin, and resveratrol — often proposed for the treatment of cystic fibrosis (CF). The review concluded that while the mechanisms by which these substances function should be further investigated as potential drug treatments, there is little evidence…